Form 4: ANAB CFO Sells Shares for Tax Obligations

AnaptysBio's CFO, Dennis Mulroy, sold 3,363 shares of common stock at $43.26 to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Dennis Mulroy, Chief Financial Officer of AnaptysBio, Inc. (ANAB), reported transactions involving the company's common stock and restricted stock units (RSUs).
• On January 3, 2026, 8,292 restricted stock units vested and converted into 8,292 shares of common stock for no consideration.
• Following this conversion, Mulroy's direct beneficial ownership of common stock increased to 17,693 shares.
• On January 5, 2026, Mulroy sold 3,363 shares of AnaptysBio common stock at a price of $43.26 per share.
• This sale was a 'sell to cover' transaction, executed solely to satisfy tax withholding obligations in connection with the RSU vesting and was not a discretionary sale.
• After the sale, Mulroy directly beneficially owned 14,330 shares of common stock and 16,585 restricted stock units.
• The RSUs vest as to 25% of the total annually, commencing on January 3, 2025, contingent on Mulroy's continued provision of service to the Issuer.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary insider transaction related to RSU vesting and tax obligations, which is generally considered neutral in terms of company sentiment.

Positives

• The vesting of 8,292 restricted stock units represents a realized gain for the CFO and an increase in direct common stock ownership prior to the tax-related sale.
• The RSU vesting schedule, with 25% vesting annually starting January 3, 2025, provides a structured long-term incentive for the Chief Financial Officer.

Negatives

• A reduction of 3,363 shares in direct common stock ownership due to the 'sell to cover' transaction, although this was non-discretionary.

Risks

• N/A

Future Outlook

N/A

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

N/A

Comparison to Industry Standards

• N/A

Legal Proceedings

• N/A

Related Party Transactions

• N/A

Stakeholder Impact

• Shareholders: A minor, routine reduction in direct insider ownership due to tax obligations, unlikely to significantly impact investor perception or share price.
• Employees (specifically the CFO): The vesting and subsequent sale represent a realization of compensation, aligning executive incentives with company performance.

Next Steps

• Continued vesting of remaining restricted stock units annually, subject to the CFO's provision of service to the Issuer.

Key Dates

Recommendation

This Form 4 details a routine 'sell to cover' transaction by the CFO to satisfy tax obligations arising from RSU vesting. It is a non-discretionary event and does not reflect a change in management's outlook or a strategic move. Therefore, it provides no new information that would warrant a change in investment recommendation; a 'hold' stance remains appropriate based solely on this filing.

Keywords

ANAB, AnaptysBio, Form 4, Insider Transaction, Stock Sale, Restricted Stock Unit, CFO, Tax Withholding